Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992442 | 0.93 | P2RY6 (0.43) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL4082385 | 0.93 | P2RY6 (0.43) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL1096600 | 0.93 | P2RY6 (0.43) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL19305223 | 0.88 | TMIGD3 (0.36) | ABL1RIN1ADORA3TYMPALDH1A1 | |
| SCHEMBL25630050 | 0.85 | ABL1 (0.41) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL20394006 | 0.85 | P2RY6 (0.42) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL4083482 | 0.84 | P2RY6 (0.39) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL20484818 | 0.82 | ABL1 (0.41) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL6424816 | 0.82 | TYMP (0.43) | ADORA3TYMP | |
| SCHEMBL6878873 | 0.82 | POLB (0.47) | P2RY6P2RY14NT5EABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | P2RY6 237/4885P2RY14 166/4885NT5E 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.